Albera Salut S.L.P.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Albera Salut S.L.P. includes studies in cardiovascular diseases focused on people with hypertension, high cardiovascular risk, and established cardiovascular disease. The trials are designed to assess whether new approaches can better reduce serious heart and vascular complications.
- Evaluating strategies for hypertension that is not adequately controlled
- Studying prevention of major cardiovascular events such as heart attack, stroke, and heart failure-related complications
This work aims to improve treatment effectiveness and lower the risk of life-threatening outcomes for patients with ongoing cardiovascular concerns.
Immune System Diseases
The site also supports research in immune system diseases, with a strong focus on preventing Herpes Zoster in older adults. These studies look at how well immune-based prevention can protect against shingles and maintain that protection over time.
- Assessing the long-term protection of a vaccine against Herpes Zoster
- Examining the persistence of the immune response in older populations
This research is intended to support better prevention of shingles and improve understanding of lasting immune protection.
Virus Diseases
In the area of virus diseases, the clinical trials at this research site are centered on infection prevention and immune protection, especially for conditions caused by viral reactivation. The main disease under study is Herpes Zoster, with attention to reducing disease occurrence in adults at higher risk.
- Testing a vaccine approach to help prevent Herpes Zoster
- Supporting research on durable protection against viral disease in older adults
The overall goal is to improve preventive care against viral illness and strengthen protection in vulnerable patient groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Albera Salut S.L.P.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Evaluation of Efficacy, Safety, and Immune Response Persistence of Recombinant Varicella Zoster Virus Glycoprotein E Vaccine in Herpes Zoster Prevention in Older Adults | GlaxoSmithKline Biologicals | Phase III | Not Recruiting | Aug 2022 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Recombinant Varicella Zoster Virus Glycoprotein E | 1 | Unknown | 2022-08-08 | 2022-08-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.